Memphasys Ltd (AU:MEM) has released an update.
Memphasys Ltd is advancing its Felix™ System for equine fertility with a three-year study, aiming for commercial outcomes within a year. The innovative system promises to enhance sperm quality and speed in the equine breeding market, valued at over $681 million. This move positions Memphasys to capture significant market share, particularly in the non-thoroughbred sector.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
